Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Walmart, Eli Lilly and Company, Intuitive Surgical, UnitedHealth Group, and Abbott Laboratories are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

The Astoria US Equal Weight Quality Kings ETF focuses on high-quality U.S. companies. Click here to read my most recent analysis of the ROE ETF.

While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them ...

In a randomized trial, Mass General Brigham researchers found the surgical removal of tonsils and adenoids was effective for children with snoring and ...

These ETFs can add some stability to any portfolio. The post 3 defensive ETFs to navigate volatility on the ASX appeared ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...